Navigation Links
The Institut Curie and Ipsogen Sign a Scientific Collaboration Agreement Relating to the Genomic Grade, a Molecular Diagnostic Tool for Breast Cancer
Date:1/11/2010

PARIS and MARSEILLE, France, January 11 /PRNewswire-FirstCall/ -- The INSTITUT CURIE and IPSOGEN (FR0010626028 - ALIPS) announce the signing of a scientific collaboration agreement in the breast cancer domain. Within the framework of this project, the current scientific knowledge on Ipsogen's MapQuant Dx Grade Genomic, HER2 and HR tests will be increased thanks to new data established from a large population of patients treated at the Institut Curie. The aim of this collaboration is to evaluate these tests compared to current breast cancer characterization techniques. Indeed, these new tests could represent, for oncologists and pathologists, helpful decision-making tools enabling them to improve the diagnostic process and optimally adapt their therapeutic strategy to each patient.

Within the framework of this collaboration, the genomic analysis of 200 breast tumors will be performed on the Institut Curie's molecular diagnostic platform, using the expertise of the Institut Curie, in particular the translational research department and clinical teams specialized in breast cancer, and Ipsogen.

Sergio Roman-Roman, Head of Translational Research at the Institut Curie, states: "the existence, at the Institut Curie, of a bank of well-characterized human tumor samples, as well as a particularly strong genomic analysis platform, makes it possible to conduct a reliable assessment of molecular diagnostic tools such as the one that is the subject of this collaboration. The stakes are high because these tools, once validated via research such as those we are beginning today, can be a substantial aid to making therapeutic decisions for women with breast cancer."

Vincent Fert, CEO of Ipsogen, adds: "This first collaboration with the Institut Curie is very important for our company, and reflects the recognition of the quality of our development work. By pooling the complementary scientific and clinical know-how of the Institut Curie and the technical and industrial know-how of Ipsogen, it will be possible to make faster progress towards personalized medicine. It will also enable us, as we have already successfully done in onco-hematology, to continue collaborating with oncologists to develop products that meet their clinical needs in breast cancer."

About the Institut Curie

The Institut Curie is a private non-profit foundation that combines France's largest oncology research center and a state-of-the-art hospital that has pioneered many treatments. It is a reference center in breast cancer, tumors in children and adolescents and eye cancers, and disseminates medical innovations nationwide and worldwide.

Founded in 1909 on a model designed by Marie Curie and still cutting-edge, "from basic research to innovative healthcare," the Institut Curie has some 2,000 researchers, physicians and healthcare staff who all work towards a common goal: to defeat cancer.

A vital link between clinicians and scientists, the Institut Curie's translational research department forms a bridge from research progress to hospitals and industry. This department's competence in genomics, post-genomics, immunomonitoring, pharmacology and biology complement the Institut Curie's scientific and clinical activity.

About IPSOGEN

IPSOGEN, Cancer Profiler, develops and markets molecular diagnostic tests that help map diseases to guide oncologists and patients in their therapeutic decisions.

Strengthened by its scientific and clinical partnerships with recognized academic centers, and its multidisciplinary teams in France and the USA, and with more than 70 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, Ipsogen is now targeting breast cancer with the aim of providing currently inaccessible diagnostic information.

Ipsogen employed 60 people as of June 30, 2009. Its headquarters are located in Marseille, France, with a subsidiary, Ipsogen Inc., in Stamford, CT, USA.

For more information, visit http://www.ipsogen.com

SOURCE Ipsogen SA


'/>"/>
SOURCE Ipsogen SA
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Better Hearing Institute Publishes First Comprehensive Guide to Financial Assistance for Hearing Aids
2. Institute of Medicine recommends stricter resident duty hour regulations to prevent medical errors
3. The Black AIDS Institute Kicks Off Its National Platform to Build Black AIDS Awareness
4. The Black AIDS Institute Kicks Off Its National Platform to Build Black AIDS Awareness in Atlanta, GA
5. Vend Marketing Institute Calls on Congress to Modify Calorie Disclosure Requirement: Supports Existing Disclosure Which Is More Complete and Effective
6. Mimotopes Awarded a Major Peptide Library Supply Agreement by La Jolla Institute for their Studies Screening Dengue and Tuberculosis Pathogens
7. Aging Institute Reveals 2010 Trends
8. Laser Spine Institute (LSI) Supports Jingle Bell Run
9. NIH awards La Jolla Institute $18.8 million for major infectious disease study
10. San Diego Hospice and The Institute for Palliative Medicine on the Passing of Sol Price
11. Rush Limbaugh & Michael Steele Join Tea Party Support & Social Security Institute-Demand GOP Senate Stop ObamaCare by Any Means Possible
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... a startling report released today, National Safety Council research ... proven plan to eliminate prescription opioid overdoses. Prescription Nation ... tackling the worst drug crisis in recorded U.S. history, assigned a ... , New Mexico , Tennessee ... failing states, three – Michigan , ...
Breaking Medicine Technology: